Chronic Back Pain - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 47 pages report, published by Global Markets Direct

Keywords : Chronic Back Pain Therapeutic Products under Development, Key Players in Chronic Back Pain Therapeutics, Chronic Back Pain Pipeline Overview, Chronic Back Pain Pipeline, Chronic Back Pain Pipeline Assessment

Report ThumbnailSeptember-2013
Chronic Back Pain - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Chronic Back Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Back Pain. Chronic Back Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Back Pain.
- A review of the Chronic Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Back Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Chronic Back Pain, H2 2013 7
  • Products under Development for Chronic Back Pain - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Chronic Back Pain, H2 2013 7
  • Products under Development for Chronic Back Pain - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • BioDelivery Sciences International, Inc., H2 2013 16
  • Teva Pharmaceutical Industries Limited, H2 2013 17
  • Collegium Pharmaceutical, Inc., H2 2013 18
  • Grunenthal GmbH, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Chronic Back Pain Therapeutics - Drug Profile Updates 34
  • Chronic Back Pain Therapeutics - Discontinued Products 42
  • Chronic Back Pain Therapeutics - Dormant Products 43
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Chronic Back Pain Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Chronic Back Pain 7
  • Chronic Back Pain Therapeutics under Development by Companies 9
  • Chronic Back Pain Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Chronic Back Pain Therapeutics - Products under Development by Companies 14
  • Chronic Back Pain Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Chronic Back Pain Therapeutics Development 16
  • BioDelivery Sciences International, Inc. 16
  • Teva Pharmaceutical Industries Limited 17
  • Collegium Pharmaceutical, Inc. 18
  • Grunenthal GmbH 19
  • Chronic Back Pain - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • hydrocodone bitartrate ER - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • buprenorphine hydrochloride - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • cebranopadol - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • cycloserine - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • oxycodone ER - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • AYX-2 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Chronic Back Pain Therapeutics - Drug Profile Updates 34
  • Chronic Back Pain Therapeutics - Discontinued Products 42
  • Chronic Back Pain Therapeutics - Dormant Products 43
  • Chronic Back Pain - Product Development Milestones 44
  • Featured News & Press Releases 44
  • Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 44
  • Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 44
  • Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 45
  • Appendix 46
  • Methodology 46
  • Coverage 46
  • Secondary Research 46
  • Primary Research 46
  • Expert Panel Validation 46
  • Contact Us 47
  • Disclaimer 47

Please select a license type

Share

Related Products

Global Markets DirectChronic Back Pain - Pipeline Review, H2 2013Product ThumbnailChronic Back Pain - Pipeline Review, H2 2013, Industry ReportProduct #: 113317
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved